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Summary
Nearly three-quarters of patients with breast cancer have some form of depression. The main cause of the depression 
is fear, often lifelong, concerning the diagnosis of cancer itself, eventual recurrence, appearence of metastases, fi nal outcome 
of the desease, but also the possible surgical mutilationof the patient and possible genetic transmission of malignant desease 
to the off springs. The high incidence of mental disorders in patients with malignant diseasesrequires the inclusion of psy-
chiatrist in the therapy team. This could ameliorate the patients quality of life and infl uence the kind of therapy applied, as 
well as the fi nal outcome of the disease.
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PSIHO-ONKOLOŠKI PRISTUP OBOLJELIMA OD RAKA DOJKE
Sažetak
Gotovo tri četvrtine oboljelih od karcinoma dojke ima neki oblik depresije. Depresija je najčešće uzrokovana strahom, 
često cjeloživotnim, zbog dijagnoze maligne bolesti, kao i zbog stalne mogućnosti povrata bolesti i neizvjesnog ishoda 
liječenja. Eventualna kirurška mutilacija bolesnika, kao i mogući genetički prijenos maligne bolesti na potomsvo, također 
mogu uzrokovati strah i depresiju kod bolesnika. Budući da je pojavnost psihičke promijenjenosti kod oboljelih od malignih 
bolesti velika, smatra se da je uključenost psihijatra u liječenje bolesnika s malignim bolestimaneophodna. Time se omogućuje 
bolja kvaliteta života bolesnika i povoljniji ishod liječenja.
KLJUČNE RIJEČI: psiho-onkologija, liaison psihijatrija, rak dojke, mentalni poremećaji
INTRODUCTION
Mental disturbances are not rare in female 
breast cancer patients, and it is known that they can 
also have a signifi cant impact on the selection and 
course of treatment, as well as the outcome 
of the illness itself. The literature thus states that 
70% breast cancer patients have depressive disor-
ders and more than half of them comply with the 
diagnosis of psychic disturbance. Most frequent 
psychic disturbances are adjustment disorders 
(68%), major depressive episodes (13%) and deliri-
ous conditions (8%) (1). It is a known fact that de-
pressive condition has an unfavourable impact on 
the outcome of the illness, and some people think it 
triggers the cancer occurrence. The results obtained 
by a meta-analysis of 31 prospective studies have 
shown that the mortality increase is 25% in patients 
with depressive disorders and as much as 39% in 
patients with major depressive disorders (2).
FACTORS AFFECTING THE PROBLEM
A few factors can seriously shake the psychic 
stability of female patients with a diagnosed breast 
cancer.Already the knowledge that a person suf-
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fers from a malignant tumour is an extreme psy-
chic stress for her. The basic emotion that appears 
is the fear of death, also fear of disability, fre-
quently a lifelong fear of appearance of recur-
rence, metastases or a malignant tumour located 
somewhere else. The expected mutilation, except 
for the noticeable deformity, is an additional psy-
chic burden because female patients think that 
they lose their att raction, especially sexual att rac-
tion, which frequently implies huge diffi  culties for 
single women to fi nd partners, and thus to have 
children, and the fear of leaving and loss of family 
for married women. Therapeutic protocols fre-
quently include a lengthy treatment, the conse-
quences and complications of which (fatigue, ex-
haustion, hair loss, haemorrhage, changes in irra-
diated skin, hormonal imbalance and other) 
additionally psychologically exhaust female pa-
tients. Mental condition can also deteriorate due 
to brain metastases and associated illnesses and 
disorders (uraemia, encephalopathy, electrolyte 
disorders and other).
PREVALENCE AND TYPES 
OF DISTURBANCES
The dominant fear and depression, sometimes 
there are also anger and self-accusation, even sui-
cidal ideas. Although suicidal ideas are relatively 
frequent, the current suicide incidence is only 
somewhat higher that in the general population. 
Suicidal tendencies are facilitated by depression 
and despair, poorly controlled pain, feeling of help-
lessness, disinhibition within the scope of organ 
syndrome, exhaustion, anxiety, pre-existing psy-
chopathology (drugs abuse, character pathology 
and other), diffi  cult family situation and positive 
family anamnesis to suicide. Delirious conditions 
are not rare in terminal stages of illness, and they 
can be developed as the consequence of metabolic 
encephalopathy, failure of vital organs, electrolyte 
disorders, hypoxia, nutritive defi ciency, infection 
(especially in immunosuppressed disorders), as 
well as endocrine disorders.
THERAPY
Individual approach
Patients are nowadays loaded with informa-
tion from the Internet, which substitutes conver-
sations with a physician, and which is often un-
critically interpreted by patients. This is why they 
literary plead for someone to whom they could 
entrust their fears and who could psychically up-
lift them.Which is why mental support is neces-
sary from the very moment of diagnosis to the 
end of treatment, and to many even afterwards, 
whereby a psychiatrist has a signifi cant role in the 
medical team.
Unfortunately, both physicians and patients 
frequently see depression as an expected and nor-
mal reaction to the announced diagnosis, which is 
why depression is often unrecognized and un-
treated (3-8). It would be desirable that a psychia-
trist is present as early as when announcing the 
diagnosis, which has until now most often been 
done by a surgeon that would also perform the 
surgery on a patient. His or her role is primarily to 
perform a surgery well, and to inform the patient 
about the nature of the surgery. Owing to the na-
ture of his or her work, this conversation with the 
patient is usually short, while at that moment the 
patient needs a longer conversation, explanation, 
empathy and encouragement. The patient needs 
to be receive the diagnosis, but also needs to be 
encouraged the patient. A physician should avoid 
reprovingly shaking his or her head and asking 
the patient where she has been until now and how 
could she let the tumour spread so much. On the 
other hand, she needs to be given hope in the 
treatment, describe the possibilities of plastic sur-
gery and reconstruction to her, possibly with a 
video, and announce a lengthy treatment, its pos-
sible complications and consequences, and help 
her to accept the proposed treatment modes from 
the team. Of course, no psychiatrist is needed for 
something like that, but he or she should be there 
to make the best judgment of the patient’s reac-
tion, and based on it to help in the establishment 
of the most adequate therapy.
Psychosocial approach
In addition to the individual psychothera-
peutic approach (psychological interventions to 
reduce depression and anxiety), psycho-social ap-
proach (inclusion of the family) is also important. 
Group psychotherapy would also be used because 
the confrontation with the similar healed patients 
could stimulate the positive att itude to such ill-
ness. If possible, such patients should return to 
their work environment as soon as possible, 
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whereby they would be less focused on their ill-
ness.
Pharamceutical approach
A psychiatrist will decide upon the adminis-
tration of psychopharmaceuticals depending on 
the seriousness and type of disorder. A systematic 
review of 24 randomized controlled trials of either 
pharmacologic or psychotherapeutic interven-
tions for cancer patients with depression or de-
pressive symptoms has recently concluded that 
depression in cancer patients is responsive to anti-
depressant medication treatment , although some 
studies reported high dropout rates and some 
failed to report adverse events and tolerability (9). 
Studies have proven impacts of selective inhibi-
tors of serotonin storage; primarily paroxetine (10) 
and fl uoxetine (11). In the treatment of comorbid 
neuropathic pain in addition to depression, the 
choice is venlafaxine, and tricyclic antidepressants 
(amitriptyline and desipramine) and bupropion 
(12-14). Mirtazapine has proven especially effi  -
cient in female patients with cachexia (15). Toler-
ability of the above stated antidepressants is fre-
quently very good. The length of the treatment is, 
by all means, strictly individual, and sometimes, 
although rarely, also life-long.
CONCLUSION
Mental disturbances in breast cancer patients 
are the consequence of stress due to the diagnosis 
of malignant desease, fear of surgical mutilation’s 
consequences on a personal as well as on a family 
level, frequently premature and sudden meno-
pause caused by a hormonal therapy or oophorec-
tomy, consequences of chemo-or radiotherapy, 
etc. Very often a life-long fear of desease recur-
rence, or of appearance  of metastasisare present 
by the patients. Since diff erent mental disorders 
are common in breast cancer patients, (although 
often neglected), we think that a psychiatric ap-
proach is obligatory in the team that decides upon 
breast cancer patients treatment.
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